Home Cart Sign in  
Chemical Structure| 1374258-43-1 Chemical Structure| 1374258-43-1

Structure of 1374258-43-1

Chemical Structure| 1374258-43-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 1374258-43-1 ]

CAS No. :1374258-43-1
Formula : C8H4BrF3N2
M.W : 265.03
SMILES Code : FC(C1=CC(Br)=CC2=C1NN=C2)(F)F
MDL No. :MFCD21602947
InChI Key :YLMFTTBYMVQLMH-UHFFFAOYSA-N
Pubchem ID :67491372

Safety of [ 1374258-43-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Computational Chemistry of [ 1374258-43-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 14
Num. arom. heavy atoms 9
Fraction Csp3 0.12
Num. rotatable bonds 1
Num. H-bond acceptors 4.0
Num. H-bond donors 1.0
Molar Refractivity 48.8
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

28.68 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.58
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

3.13
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

4.5
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

2.9
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

3.65
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

3.15

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-3.86
Solubility 0.0362 mg/ml ; 0.000137 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-3.4
Solubility 0.105 mg/ml ; 0.000397 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-4.65
Solubility 0.00592 mg/ml ; 0.0000223 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Moderately soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.69 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<0.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.9

Application In Synthesis of [ 1374258-43-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1374258-43-1 ]

[ 1374258-43-1 ] Synthesis Path-Upstream   1~2

  • 1
  • [ 864539-96-8 ]
  • [ 1374258-43-1 ]
YieldReaction ConditionsOperation in experiment
57.5%
Stage #1: With potassium acetate; acetic anhydride In chloroform at 0 - 20℃; for 1 h;
Stage #2: With tert.-butylnitrite In chloroform at 60℃;
To a mixture of 133-S2(700 mg, 2.77 mmol) and potassium acetate (325.8 mg, 3.32 mmol) in CHC13 (20 mL) was addeddropwise acetic anhydride (846.6 mg, 8.30 mmol) at 0 °C. The resulting mixture was stirred at room temperature for 1 hour. The reaction mixture was heated to 60 °C and tert-butyl nitrite (570.6 mg, 5.54 mmol) was added. After stirring overnight at 60 °C, the mixture was diluted with water and extracted with DCM twice. The combined organic layers were washed with brine, dried overanhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was dissolved in MeOH (5 mL) and 6 N HC1 (5 mL). The mixture was stirred at room temperature for 4 hours, basified with 10 N aqueous NaOH solution, and extracted with DCM twice. The combined organic layers were washed with brine, dried over anhydrous Na2SO4, and concentrated under reduced pressure. The remaining residue was purified by column chromatography on silica gel (PE/EtOAc= 10:1 to 3:1) to afford 133-S3 (420 mg, 57.5percent yield) as a yellow oil. LC/MS (ESI) m/z: 265 (M+H).
52%
Stage #1: With potassium acetate; acetic acid In toluene for 0.25 h;
Stage #2: With isopentyl nitrite In toluene at 20℃; for 18 h;
To a solution of 4-bromo-2-methyl-6-(trifluoromethyl)aniline (3.3 g, 13 mmol) in toluene (65 mL) and glacial acetic acid (11.2 mL, 195 mmol) was added potassium acetate (10.2 g, 104 mmol) portionwise. After 15 minutes a large amount of precipitate had formed, hindering stirring of the reaction. The reaction was diluted with acetic acid (10 mL). Isoamyl nitrite (1.92 mL, 14.3 mmol) was then added dropwise and the reaction was stirred at room temperature for 3 hours. Additional isoamyl nitrite (0.5 mL, 3.7 mmol) was added and the reaction was left stirring for 15 hours. The reaction was diluted with water (100 mL) and stirred for 1.5 hours. The solution was partitioned between ethyl acetate and saturated aqueous sodium bicarbonate. The layers were separated and the organics were washed with brine, dried over magnesium sulfate, filtered, and concentrated. Purification by flash column chromatography (5-50percent ethyl acetate/heptanes) gave the title compound (1.78 g, 52percent) as a yellow powder. -ESI (M-H+1) 264.9; 1H NMR (400 MHz, CDCl3, δ): 8.13 (s, 1 H), 8.09-8.11 (m, 1H), 7.76 (dd, J=1.66, 0.88 Hz, 1H).
References: [1] Patent: WO2018/160889, 2018, A1, . Location in patent: Page/Page column 561; 562; 563.
[2] Patent: US2012/108619, 2012, A1, . Location in patent: Page/Page column 37.
  • 2
  • [ 88301-98-8 ]
  • [ 1374258-43-1 ]
References: [1] Patent: WO2018/160889, 2018, A1, .
[2] Patent: US2012/108619, 2012, A1, .
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 1374258-43-1 ]

Fluorinated Building Blocks

Chemical Structure| 1100212-66-5

A102573 [1100212-66-5]

7-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.86

Chemical Structure| 57631-11-5

A160296 [57631-11-5]

5-Bromo-3-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 1000341-21-8

A160986 [1000341-21-8]

3-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.78

Bromides

Chemical Structure| 1100212-66-5

A102573 [1100212-66-5]

7-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.86

Chemical Structure| 57631-11-5

A160296 [57631-11-5]

5-Bromo-3-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 635712-49-1

A135010 [635712-49-1]

5-Bromo-7-ethyl-1H-indazole

Similarity: 0.78

Trifluoromethyls

Chemical Structure| 1100212-66-5

A102573 [1100212-66-5]

7-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.86

Chemical Structure| 57631-11-5

A160296 [57631-11-5]

5-Bromo-3-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 1000341-21-8

A160986 [1000341-21-8]

3-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.78

Related Parent Nucleus of
[ 1374258-43-1 ]

Indazoles

Chemical Structure| 1100212-66-5

A102573 [1100212-66-5]

7-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.89

Chemical Structure| 1000342-95-9

A417797 [1000342-95-9]

4-Bromo-6-(trifluoromethyl)-1H-indazole

Similarity: 0.88

Chemical Structure| 1428234-73-4

A179394 [1428234-73-4]

4-Bromo-5-(trifluoromethyl)-1H-indazole

Similarity: 0.86

Chemical Structure| 57631-11-5

A160296 [57631-11-5]

5-Bromo-3-(trifluoromethyl)-1H-indazole

Similarity: 0.79

Chemical Structure| 635712-49-1

A135010 [635712-49-1]

5-Bromo-7-ethyl-1H-indazole

Similarity: 0.78